- Home
- ABT vs NVO Comparison
ABT vs NVO Comparison
Compare ABT & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABT
- NVO
- Stock Information
- Founded
- ABT 1888
- NVO 1923
- Country
- ABT United States
- NVO Denmark
- Employees
- ABT N/A
- NVO N/A
- Industry
- ABT Medical/Dental Instruments
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABT Health Care
- NVO Health Care
- Exchange
- ABT Nasdaq
- NVO Nasdaq
- Market Cap
- ABT 231.5B
- NVO 243.4B
- IPO Year
- ABT N/A
- NVO N/A
- Fundamental
- Price
- ABT $125.72
- NVO $49.89
- Analyst Decision
- ABT Strong Buy
- NVO Buy
- Analyst Count
- ABT 18
- NVO 10
- Target Price
- ABT $146.61
- NVO $80.40
- AVG Volume (30 Days)
- ABT 6.3M
- NVO 10.6M
- Earning Date
- ABT 10-15-2025
- NVO 11-05-2025
- Dividend Yield
- ABT 1.86%
- NVO 2.40%
- EPS Growth
- ABT 141.96
- NVO 24.25
- EPS
- ABT 7.96
- NVO 3.93
- Revenue
- ABT $43,843,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- ABT $7.56
- NVO $9.58
- Revenue Next Year
- ABT $7.78
- NVO $7.39
- P/E Ratio
- ABT $15.63
- NVO $13.08
- Revenue Growth
- ABT 6.37
- NVO 20.91
- 52 Week Low
- ABT $110.86
- NVO $45.05
- 52 Week High
- ABT $141.23
- NVO $113.76
- Technical
- Relative Strength Index (RSI)
- ABT 37.39
- NVO 28.27
- Support Level
- ABT $124.12
- NVO $52.38
- Resistance Level
- ABT $128.45
- NVO $53.55
- Average True Range (ATR)
- ABT 2.54
- NVO 0.99
- MACD
- ABT -0.45
- NVO -0.60
- Stochastic Oscillator
- ABT 17.35
- NVO 5.24
About ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.